CP 55,940

CP 55,940 is a synthetic cannabinoid which mimics the effects of naturally occurring THC (one of the psychoactive compounds found in cannabis). CP 55,940 was created by Pfizer in 1974 but was never marketed. It is currently used as a research tool to study the endocannabinoid system.<ref>Template:Cite journal</ref>

Pharmacology

CP 55,940 is 45 times more potent than Δ⁹-THC, and fully antagonized by rimonabant (SR141716A).<ref>Template:Cite journal</ref> It is considered a full agonist at both CB₁ and CB₂ receptors and has K_i values of 0.58 nM and 0.68 nM respectively, but is an antagonist at GPR55, the putative "CB₃" receptor.<ref>Template:Cite journal</ref> CP 55,940 binding has been detected in the cytosol of rat brain cerebral cortex.<ref>Template:Cite journal</ref> It can upregulate 5-HT_2A receptors in mice.<ref>Template:Cite journal</ref>

In vitro studies

CP 55,940 induced cell death in NG 108-15 Mouse neuroblastoma x Rat glioma hybrid brain cancer (genetically engineered mouse x rat brain cancer) cells.<ref>Template:Cite journal</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In vivo studies

CP 55,940 showed protective effects on rat brain mitochondria upon paraquat exposure.<ref>Template:Cite journal</ref>

It also showed neuroprotective effects by reducing intracellular calcium release and reducing hippocampal cell death in cultured neurons subjected to high levels of NMDA.<ref>Template:Cite journal</ref>

See also

• CP 42,096
• CP 47,497
• CP 55,244
• Cycloheptyl CP 55,940

References

{{#invoke:Navbox|navbox}} {{#invoke:Navbox|navbox}} Template:Cannabinoidergics